Pacira | PCRX - Operating Expenses



Pacira reported $170.87M in Operating Expenses for its fiscal quarter ending in June of 2025.


Operating Expenses Change Date
Astellas Pharma JPY 413.25B 17.48B Jun/2025
Bristol-Myers Squibb USD 8.5B 265M Jun/2025
Ironwood Pharmaceuticals USD 57.33M 8.63M Dec/2024
J&J USD 16.8B 8.54B Jun/2025
Ligand Pharmaceuticals USD 40.46M 41.09M Jun/2025
Novo Nordisk 42.77B 3.48B Jun/2025
Pacira USD 170.87M 3.93M Jun/2025
Perrigo USD 1B 36.2M Jun/2025
Pfizer USD 11.62B 1.58B Jun/2025
Supernus Pharmaceuticals USD 153.31M 892K Jun/2025
Teva Pharmaceutical Industries USD 3.28B 95M Jun/2025
Xeris Pharmaceuticals USD 67.06M 8.64M Jun/2025
Zoetis USD 1.44B 35M Jun/2025